CatalYm
Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
CatalYm has raised €100M across 2 funding rounds from 8 investors, most recently a Series C round in Nov 2022. Based in Munich, Germany; founded 2016; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€100M
€100,000,000
Funding rounds
2
Investors
8
distinct backers
Active since
2020-11
latest 2022-11
Funding by year
EUR raised per yearCatalYm — funding by year — interactive chart.
Data table
| CatalYm — funding by year | |
|---|---|
| 2020 | €50M |
| 2022 | €50M |
Signals
High confidenceRaise-next likelihood9
base rate 50% for Series C
- ▼ Past typical raise window
- ▼ Low backer re-investment
Exit likelihood10
base rate 11% (2+ rounds)
- ▲ €100M+ raised
- ▲ 10y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-11-23 | Series C | €50M | Bayern Kapital,BioGeneration Ventures,Brandon Capital,Coparion,Forbion,Jeito Capital+2 more | View deal → |
| 2020-11-10 | Seed | €50M | — | View deal → |
Investors
8Related news
- CatalYm Closes EUR 50M Series C Financingfinsmes.com · 2022-11
- finsmes.com
Similar companies
same sector or country- Delivery Hero€7.1BGermany · E-commerce
- Enpal€4.6BGermany · Cleantech
- Auxmoney€3.5BGermany · Fintech
- Helsing€2.9BGermany · AI
- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
Global coverage: FundingData